SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechno...

ADPT

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechno...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Adaptive Biotechnologies reported significant 46% revenue growth in 2025, chiefly driven by its MRD segment. With expanded Medicare coverage for clonoSEQ and a robust financial outlook, ADPT is well-positioned for continued growth and profitability in 2026.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>ADPT achieved 46% revenue growth in 2025, signaling strong performance.</li><li>MRD business contributed 77% of overall revenue, indicating its importance.</li><li>Expanded Medicare coverage for clonoSEQ enhances market opportunity.</li><li>Positive Adjusted EBITDA indicates improved financial health for ADPT.</li><li>Guided 2026 MRD revenue forecast of $255-$265 million.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Pfizer (PFE)</strong>: Collaboration may enhance ADPT&#039;s drug development capabilities.</li><li><strong>Flatiron Health (N/A)</strong>: Integration with ADPT&#039;s clonoSEQ could lead to increased usage.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits within Corporate Developments as it outlines ADPT&#039;s improved financial performance and strategic partnerships which are crucial for future revenue generation and market position enhancement.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Expansion of Medicare coverage may lead to new customer acquisition.</li><li>Positive Adjusted EBITDA indicates operational efficiency improvements.</li><li>Integration with Flatiron Health enhances market visibility and credibility.</li><li>Partnership with Pfizer may lead to innovative revenue streams.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q4 2025 revenue: $71.7 million, +51% year-over-year.</li><li>Full-year 2025 revenue: $277 million, +55% year-over-year.</li><li>MRD revenue for 2025: $212.3 million, +46% year-over-year.</li><li>Adjusted EBITDA for Q4 2025: $4.1 million, compared to -$16.4 million in Q4 2024.</li><li>MRD business achieved positive cash flow and Adjusted EBITDA.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Given the strong growth and positive adjustments, ADPT stock is likely to outperform in the next 12 months.</p>
  </section>
</section>


<article>
  <h2>Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results</h2>
  <p>SEATTLE, Feb. 5, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: <strong>ADPT</strong>), a biotechnology leader dedicated to translating the genetics of the adaptive immune system into clinical products, has announced its financial results for the fourth quarter and full year ended December 31, 2025. The company celebrated significant achievements throughout 2025, achieving a remarkable <strong>46% revenue growth</strong> along with profitability in its Minimal Residual Disease (MRD) segment.</p>

  <section>
    <h3>Key Highlights from 2025</h3>
    <ul>
      <li><strong>Revenue:</strong> $71.7 million for Q4 and $277.0 million for the entire year.</li>
      <li><strong>MRD Contribution:</strong> Constituted 86% of Q4 revenue and 77% of total annual revenue.</li>
      <li><strong>Growth Rates:</strong> 54% increase in MRD revenue in Q4 and 46% for the full year.</li>
      <li><strong>Test Volume Expansion:</strong> clonoSEQ® tests delivered rose by 39% year-over-year, totaling 105,587 tests in 2025.</li>
      <li><strong>Regulatory Milestones:</strong> Expanded Medicare coverage for clonoSEQ in monitoring mantle cell lymphoma.</li>
      <li><strong>Partnerships:</strong> Secured two non-exclusive licensing agreements with Pfizer Inc.</li>
    </ul>
  </section>

  <section>
    <h3>Fourth Quarter Financial Results</h3>
    <p>In Q4 2025, Adaptive Biotechnologies reported a revenue of <strong>$71.7 million</strong>, reflecting a <strong>51% increase</strong> from the prior year's fourth quarter. Notably, excluding revenue from the Genentech Agreement, revenue surged by <strong>63%</strong> compared to the same period last year. The MRD business alone generated <strong>$61.9 million</strong>, marking a <strong>54% increase</strong>.</p>
    <p>The company also recognized performance improvements in operational metrics. Operating expenses were <strong>$84.5 million</strong>, slightly up from <strong>$81.3 million</strong> in Q4 2024. Meanwhile, the net loss decreased significantly to <strong>$13.6 million</strong> from <strong>$33.7 million</strong> a year earlier.</p>
    <p>Adjusted EBITDA stood at <strong>$4.1 million</strong> for the quarter, a turnaround from a loss of <strong>$16.4 million</strong> in Q4 2024, showcasing progress in financial health.</p>
  </section>

  <section>
    <h3>Annual Financial Overview</h3>
    <p>For the full year 2025, Adaptive Biotechnologies reported a revenue of <strong>$277.0 million</strong>, a significant <strong>55% increase</strong> over 2024. When excluding the Genentech Agreement, the adjusted revenue was <strong>$235.7 million</strong>, reflecting a solid <strong>42% growth</strong>.</p>
    <p>The MRD segment achieved <strong>$212.3 million</strong> in revenue, up by <strong>46%</strong>, while Immune Medicine revenue soared by <strong>93%</strong> to <strong>$64.6 million</strong>. The total operational expenses were managed at <strong>$334.1 million</strong>, down compared to <strong>$341.5 million</strong> in the previous year, indicating effective cost control measures.</p>
  </section>

  <section>
    <h3>Financial Guidance for 2026</h3>
    <p>Looking ahead, Adaptive Biotechnologies forecasts full-year revenue for the MRD business to be in the range of <strong>$255 million to $265 million</strong>. However, no specific revenue guidance for the Immune Medicine division has been provided at this time. The expected total operating expenses for the company are projected to be between <strong>$350 million and $360 million</strong>.</p>
  </section>

  <section>
    <h3>Upcoming Events and Additional Information</h3>
    <p>Management will discuss these financial results in detail during a conference call scheduled for February 5, 2026, at 4:30 PM Eastern Time. Interested parties can access the call via the company’s investor relations website at <a href="http://investors.adaptivebiotech.com">Adaptive Biotechnologies Investor Relations</a>.</p>
  </section>

  <section>
    <h3>About Adaptive Biotechnologies</h3>
    <p>Adaptive Biotechnologies is at the forefront of using the adaptive immune system's biology to develop innovative clinical diagnostics and treatment options. With proprietary platforms, the company aims to transform how diseases such as cancer are diagnosed and treated.</p>
  </section>
</article>

Adaptive Biotechnologies reported significant 46% revenue growth in 2025, chiefly driven by its MRD segment. With expanded Medicare coverage for clonoSEQ and a robust financial outlook, ADPT is well-positioned for continued growth and profitability in 2026.

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News